D-aspartic-beta-hydroxamate

Drug Profile

D-aspartic-beta-hydroxamate

Alternative Names: DAH

Latest Information Update: 28 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSERM
  • Class Antivirals
  • Mechanism of Action Ribonucleoside diphosphate reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 08 Nov 2000 No-Development-Reported for HIV infections treatment in France (Unknown route)
  • 02 Jul 1998 A study has been added to the Viral infections pharmacodynamics section
  • 30 Dec 1994 A study has been added to the Viral infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top